Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: Implications for prostate cancer detection and chemoprevention

Cancer Prevention Research

Volumn 1, Issue 3, 2008, Pages 167-173

  Lucia, M Scott ^a   Darke, Amy K ^b   Goodman, Phyllis J ^b   La Rosa, Francisco G ^a   Parnes, Howard L ^c   Ford, Leslie G ^c   Coltman Jr , Charles A ^d   Thompson, Ian M ^e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Southwest Oncology Group   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BIOPSY; CANCER DIAGNOSIS; CANCER INVASION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CHEMOPREVENTION; EARLY DETECTION OF CANCER; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; ORGAN SIZE; PLACEBOS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 61749093320     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0078     Document Type: Review

References (31)

1. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995;274:1445-9.
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
3. Loeb S, Catalona WJ. What to do with an abnormal PSA test. Oncologist 2008;13:299-305.
4. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. JAMA 1997;277:1452-5.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate- specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
6. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70.
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
8. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277:1456-60.
9. Carter HB. Prostate cancers in men with low PSA levels-must we find them? N Engl J Med 2004; 350:2292-94.
10. 1c) prostate cancer. JAMA 1994;271:368-74.
11. 1c adenocarcinoma of the prostate. J Urol 1997;157: 2206-9.
12. Noguchi M, Stamey TA, Mcneal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001; 166:104-9.
13. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
14. Fleming ID, Cooper JS, Henson DE, et al. American Joint Committee on Cancer Staging manual19975th ed Philadelphia: Lippincott 219-22.
15. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005;66:356-60.
16. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98: 1128-33.
17. Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177:1749-52.
18. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83.
19. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003;289:1414-20.
20. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975- 2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-99.
21. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the U.S. prostate cancer mortality decline. Cancer Causes Control 2008;19:175-81.
22. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wenberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population- based study. J Natl Cancer Inst 1996;88: 166-73.
23. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002;325:740.
24. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-8.
25. 1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160: 2407-11.
26. Carter HB, Walsh PC, Landis P, Epstein JL. Expectant management of prostate cancer with curative intent: preliminary results. J Urol 2002;167: 1231-4.
27. 1c prostate tumors. A contemporary analysis. Cancer 2004; 101:2001-5.
28. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004;64:544-50.
29. Montie JE, Smith JA. Whitmoreisms: memorable quotes from Willet F. Whitmore, Jr, M.D. Urology 2004;63:207-9.
30. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR.and the CAPSURE Investigators. Treatment failure after primary and salvage therapy for prostate cancer. Likelihood, patterns of care, and outcomes. Cancer 2008; 112:307-14.
31. Walsh PC. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. J Urol 2005;174:1293.